Advanced Enzyme Technologies Limited (Advanced Enzymes; NSE: ADVENZYMES; BSE: 540025), a leading specialty biotech company, announced their unaudited financial results for the second quarter and half year ended September 2026. The company reported a revenue of ₹ 2,145 million in Q2 FY27, marking a 16% year-on-year growth compared to ₹ 1,845 million in Q2 FY26. Moreover, the profit after tax (PAT) grew by 14% to ₹ 512 million in Q2 FY27 from ₹ 447 million in Q2 FY26.

Financial Highlights

The consolidated EBITDA during Q2 FY27 stood at ₹ 721 million, a 20% increase from ₹ 601 million in the same quarter of the previous year. The EBITDA margin improved to 34% compared to 33% in Q2 FY26. The earnings per share (EPS) also rose to ₹ 4.33 in Q2 FY27 from ₹ 3.87 in Q2 FY26.

Segmental Performance

The Human Nutrition segment recorded a 6% year-on-year growth to ₹ 1,285 million. The Animal Nutrition segment saw a significant 37% growth to ₹ 265 million. The Bio-Processing segment delivered robust performance with a 43% year-on-year increase to ₹ 365 million. The Specialized Manufacturing segment contributed 25% growth to ₹ 231 million.

Therefore, the company’s diversified segments are driving consistent growth, positioning Advanced Enzyme Technologies Limited for a strong future.

Source: NSE Corporate Announcement

Fundamental & Technical Analysis of Advanced Enzyme Technologies Limited

Advanced Enzyme Technologies Limited belongs to the Basic Materials › Specialty Chemicals sector. Here’s a quick read on where the business and the stock stand today.

Advanced drops 16.7% over three months and trades near its 52-week lows. Premium net margins of 22.1% demonstrate strong cost discipline and a wide competitive moat. Not a single revenue dip or loss quarter in five years — this is a business built to last through cycles. The stock sits at 9% of its 52-week range, close to annual lows. Historically, value investors build positions at these levels — though cheap stocks can stay cheap. Revenue grows at 11.3% and profits at 16.9% CAGR, with D/E of 0.00. Meanwhile, the stock dips 16.7% in three months without any fundamental deterioration. Consequently, the stock quietly becomes cheaper relative to earnings power. For long-term investors, that is a feature. Check Fundamentals of Advanced Enzyme Technologies Limited.

Advanced Enzyme Technologies Limited (ADVENZYMES) fell -5% to ₹305.5 on the NSE on 10 Aug 2026, backed by the release of its Q1 FY27 results showing a 2% rise in revenue but a 5% decline in profit after tax (PAT). The stock is now approaching resistance at ₹306, just 0.1% away. In the specialty chemicals sector, ADVENZYMES plays a crucial role in biotech solutions, and today’s move seems to be more company-specific rather than a sector-wide trend.

Technical setup — trendlines & DMA

Currently, ADVENZYMES is trading just below the 6M resistance trendline at ₹305.81, indicating a breakdown from this level. The 6M support trendline stands at ₹281.16, which is 7.97% below today’s price, offering a buffer if further downside occurs. The 50-DMA at ₹341.8 is above the 200-DMA at ₹316.0, signaling a bullish trend, though the stock is currently in recovery mode, trading above the 200-DMA but below the 50-DMA. In terms of its 52W range of ₹251.9–₹419.0, the current price is in the lower third, suggesting there is room for upside given its -27.1% distance from the 52W high.

Fundamentals & business context

With a PE of 21.7 and a profit margin of 22.6%, ADVENZYMES appears reasonably valued, especially considering its revenue CAGR of 11.3% and profit CAGR of 16.9% over the past five years. The market seems to be pricing in stable growth and profitability, though the recent decline in PAT may raise some concerns. Institutional holding at 19.3% indicates a moderate level of confidence from smart money, though not overwhelmingly bullish. There was no new NSE catalyst today beyond the Q1 results.

Algorithmic scorecard

The overall algorithmic scorecard reflects a balanced view of ADVENZYMES, with strong fundamental metrics offsetting weaker technical signals. The excellent efficiency score, driven by a 22.6% profit margin, highlights the company’s ability to maintain strong profits. The very low debt score, with a D/E ratio of 0.03, underscores its excellent financial health. On the technical side, the bearish sentiment score, with more down days than up days in the last 30, and the mixed momentum score, reflecting inconsistent price growth, are areas of concern. These technical weaknesses suggest that while the business fundamentals are solid, the stock’s price action has been volatile and unpredictable.

Company outlook

Management provided a steady business outlook with a focus on optimizing capacity allocation and improving supply chain efficiencies. They anticipate healthy growth from the Indian market across all segments and expect margins to remain stable with possible 1-2% variability. Plans include increasing R&D expenditure by INR 50 million and CapEx by INR 50 crores, with the operationalization of a new R&D center in Nashik in the latter half of FY26. Additionally, there are plans for potential capacity expansion in one of the subsidiary companies by September and a strategic focus on increasing revenue share from existing customers and expanding into new markets.

Get all details on ADVENZYMES — P&L, peers, shareholding and more on TradeAlone.

Advanced Enzyme Technologies Limited (Advanced Enzymes; NSE: ADVENZYMES; BSE: 540025), a leading specialty biotech company, announced their unaudited financial results for the first quarter ended June 2026. The total revenue from operations grew by 2% year-on-year to ₹1,898 million in Q1 FY27 from ₹1,859 million in Q1 FY26. However, the profit after tax (PAT) de-grew by 5% to ₹386 million compared to ₹404 million in the same quarter last year.

Financial Highlights

The consolidated EBITDA during Q1 FY27 stands at ₹510 million as compared to ₹564 million in Q1 FY26, a decrease of 10%. Profit before tax (PBT) stands at ₹535 million during Q1 FY27 as against ₹598 million in Q4 FY26, a decrease of 10%. The EBITDA margin stands at 27%, PBT margin at 28%, and PAT margin at 20% during the quarter.

Segmental Performance

The Human Nutrition segment declined by 7% year-on-year to ₹1,139 million in Q1 FY27, compared with ₹1,221 million in Q1 FY26. The Animal Nutrition segment reported a 3% year-on-year decline to ₹252 million in Q1 FY27, compared with ₹260 million in Q1 FY26. The Bio-Processing segment delivered a strong performance during the quarter, with revenue increasing by 30% year-on-year to ₹306 million in Q1 FY27 from ₹236 million in Q1 FY26.

The Specialized Manufacturing segment contributed 11% to the Company’s total revenue during the quarter, with revenue increasing by 41% year-on-year to ₹200 million. Geographically, domestic sales accounted for ₹937 million in Q1 FY27 as compared to ₹979 million in Q1 FY26, lower by 4%. The total revenue comprises of international sales amounting to ₹961 million in Q1 FY27 as compared to ₹881 million in Q1 FY26, an increase of 9%.

Advanced Enzymes remains committed to enhancing and strengthening its business model by maintaining a strong focus across its three key segments —Human Nutrition, Animal Nutrition, and Bio-Processing.

Source: NSE Corporate Announcement

Fundamental & Technical Analysis of Advanced Enzyme Technologies Limited

Advanced Enzyme Technologies Limited belongs to the Basic Materials › Specialty Chemicals sector. Here’s a quick read on where the business and the stock stand today.

Advanced falls 9.2% over three months and has not found a floor yet. Premium net margins of 22.6% demonstrate strong cost discipline and a wide competitive moat. Not a single revenue dip or loss quarter in five years — this is a business built to last through cycles. The stock gains 1.8% in the last month, recovering from the three-month slide. However, it is too early to call this a confirmed reversal. Revenue grows at 11.3% and profits at 16.9% CAGR, with D/E of 0.03. Meanwhile, the stock dips 9.2% in three months without any fundamental deterioration. Consequently, the stock quietly becomes cheaper relative to earnings power. For long-term investors, that is a feature. Check Fundamentals of Advanced Enzyme Technologies Limited.